George Fromm

Company: Shattuck Labs

Job title: Chief Scientific Officer

Seminars:

Leaders’ Fireside Chat:The Potential of Macrophage Therapies & Securing a Successful Future 9:00 am

Consolidating clinical advances and robust data from the past year to instill in vivo proof of efficacy Identifying preclinical programs with exciting potential and novel strategies to target macrophages Reviewing current hurdles the field is facing, in research as well as funding, and plotting methods to increase awareness and investment into the spaceRead more

day: Day Two

Dual CD47 Blockade & CD40 Immune Activation in Patients Treated With SL-172154 (SIRPα-Fc-CD40L), Results in M1 Macrophage Polarization & Evidence of Adaptive Immune Activation, Including Increased CD8 & GZMB in the TME 8:30 am

SL-172154, a hexameric bi-functional fusion protein consisting of SIRPα linked to CD40L via an inert Fc domain, was designed to simultaneously block CD47 and provide immune co-stimulation to CD40+ immune cells SL-172154 was tolerable as a monotherapy in patients with heavily pretreated platinum resistant ovarian cancers, and subsequently expanded into combination studies with liposomal doxorubicin…Read more

day: Day One